
On November 12, 2022 the NP Council of NNPBC is delighted to host the inaugural NP Networking Event ("NP Ball") at the Royal Vancouver Yacht Club, Vancouver, BC.
This will be an education and networking event that will bring together nurse practitioners during National Nurse Practitioner week. Through survey feedback, mentorship was identified as a priority for NPs. To meet this priority, Dr. David Wood will deliver a keynote speech addressing the importance of mentoring and modeling professionalism in clinical care. A networking opportunity will also be organized to strengthen our community connections and collegiality.
A professional photographer will be on site providing head shots during the networking segment.
Venue: Royal Vancouver Yacht Club
3811 Point Grey Rd, Vancouver BC (main level)
Time: 4:30 pm - 12:00 am
$89 / student NP members
Dinner: Three course dinner with wine options
Dress code: Formal
Ticket Sales Closed at 5pm on November 5, 2022.
Event Learning Objectives
- Enhance knowledge and understanding of the importance of mentorship and professionalism as a health care leader
- Sharpen leadership skills through collaboration and networking with internal and external partners
Program
4:30pm - 6:30pm | NP networking, professional head shots and industry engagement |
7:00pm - 8:00pm | Presentations
|
7:00pm - 9:00pm | Dinner |
9:00pm - 12:00am | Live DJ, dancing and photobooth |
Please reach out to Parveen Sangha (NP Ball Chair) psangha@nnpbc.com or Sukhi Jassar (NP Ball Executive Liaison) sjassar@nnpbc.com if you have any questions.
Login to NNPBC
Dr. Wood works as a structural and interventional cardiologist at Vancouver General and St. Paul's Hospital. He obtained subspecialty training at Lenox Hill Heart and Vascular Institute of New York. His primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating ACS, and advanced cardiac imaging. Dr. Wood has participated in over 50 live-cases and 20 first-in-human cases. Has co-authored over 300 publications which have been cited > 9000 times (h-index 55) and his work has been cited in all the major coronary artery and structural heart disease guidelines.
He recently published the 3M TAVR Study (JACC CVI), the SAFE MANTA Study (Circ CVI), and was co-principal investigator of the CIHR funded COMPLETE trial (4,041 patients, 140 centres, 31 countries) that was presented as Late Breaking Science at both ESC and TCT with simultaneous publication in NEJM and JACC. He is currently PI of the following investigator-initiated studies: the COMPLETE TAVR trial (n = 4000, 126 centres), the DISCORDANCE TAVR study (n = 50, 11 centres), the ULTRA CLOSURE study (n = 250, 7 centres), the PROTECT TAVR study (n = 130, 11 centres), and the SAFE TAVR study (n = 415, 15 centres). In May 2020, in collaboration with 15 North American Cardiovascular Society Leaders representing over 90,000 clinicians, he simultaneously published Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic in JACC, CJC, and the ATS.
Eisai Canada

Snore MD

HLS Therapeutics

HLS provides access to medications critical to physicians, patients, and their caregivers with the high-quality brand names they trust.
Victoria Primary Care Network

Medexus Pharma Canada

Medexus Pharma Canada is a Canadian-based specialty pharmaceutical company focused on the key areas of rheumatology, auto-immune disease, pediatrics, allergy, and dermatology. The company manages the licensing, registration, marketing, sales, and distribution of several innovative pharmaceutical products in Canada.
Medexus Pharma Canada leverages its extensive market knowledge and strong Canadian position as an innovator with new and existing products to deliver clinically proven safe and effective brands and consistent product value.
Novartis

AstraZeneca

Aspen Pharmacare Canada

In Canada, Aspen’s focus is on the following therapeutic areas:
- Women's Health - Linessa®
- Anesthesia – EMLA®, Xylocaine®, Sensorcaine®, Naropin®, Diprivan®
- Anti-Infectives - Septra®
- Thrombosis - Arixtra®, Orgaran®
- Endocrinology - Eltroxin®
- Oncology - Alkeran®, Myleran®, Lanvis®, Leukeran®
Miravo
